Becton, Dickinson and Company Interventional — D&A decreased by 2.5% to $192.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.0%, from $198.00M to $192.00M. Over 3 years (FY 2021 to FY 2024), Interventional — D&A shows relatively stable performance with a 0.7% CAGR.
An increase often signals significant capital investment or recent acquisitions, while a stable trend suggests consistent asset utilization.
This metric captures the non-cash expenses related to the allocation of the cost of tangible and intangible assets over...
Standard across all capital-intensive medical device manufacturers reporting segment-level depreciation and amortization.
bdx_segment_interventional_depreciation_and_amortization| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $192.25M | $192.25M | $197.25M | $197.25M | $197.25M | $197.25M | $199.75M | $199.75M | $199.75M | $199.75M | $196.50M | $196.50M | $196.50M | $196.50M | $200.00M | $198.00M | $197.00M | $192.00M |
| QoQ Change | — | +0.0% | +2.6% | +0.0% | +0.0% | +0.0% | +1.3% | +0.0% | +0.0% | +0.0% | -1.6% | +0.0% | +0.0% | +0.0% | +1.8% | -1.0% | -0.5% | -2.5% |
| YoY Change | — | — | — | — | +2.6% | +2.6% | +1.3% | +1.3% | +1.3% | +1.3% | -1.6% | -1.6% | -1.6% | -1.6% | +1.8% | +0.8% | -1.5% | -3.0% |